Table 1 Demographic and key characteristics of the samples.

From: APOEε4 potentiates the relationship between amyloid-β and tau pathologies

(A) TRIAD tau-PET cohort

CN

MCI

P value

AD

P value

No.

138

26

–

47

–

Age, years, mean (SD)

68.32 (11.54)

74.4 (5.45)

0.007

66.63 (11.34)

0.28

Male, no. (%)

53 (38)

13 (50)

0.3

20 (43)

0.61

Education, years, mean (SD)

15.17 (3.77)

14.36 (3.79)

0.84

14.89 (3.72)

0.92

APOE ε4 heterozygous, %

43 (31)

9 (34)

0.21

20 (43)

0.08

APOE ε4 homozygous, %

1 (0.7)

1 (4)

0.17

5 (10)

0.002

MMSE, mean (SD)

29.05 (1.25)

27.13 (2.39)

<0.0001

19.1 (7.31)

<0.0001

CDR SoB, mean (SD)

0.18 (0.45)

1.47 (1.23)

<0.0001

6.48 (4.08)

<0.0001

[18F]AZD4694 SUVR, (SD)

1.48 (0.42)

1.86 (0.54)

0.0001

2.42 (0.63)

<0.0001

Braak 1&2 [18F]MK6240 SUVR, (SD)

0.98 (0.24)

1.32 (0.55)

<0.0001

1.82 (0.63)

<0.0001

Braak 3&4 [18F]MK6240 SUVR, (SD)

1.09 (0.23)

1.41 (0.62)

<0.0001

2.73 (1.21)

<0.0001

Braak 5&6 [18F]MK6240 SUVR, (SD)

1.12 (0.21)

1.31 (0.38)

<0.0001

2.55 (1.23)

<0.0001

(B) ADNI tau-PET cohort

CN

MCI

P value

AD

P value

No.

157

83

–

24

–

Age, years, mean (SD)

70.98 (5.91)

70.57 (7.09)

0.63

74.11 (7.65)

0.02

Male, no. (%)

71 (45)

49 (59)

0.04

12 (50)

0.66

Education, years, mean (SD)

16.65 (2.5)

15.84 (2.85)

0.02

16.26 (2.51)

0.47

APOE ε4 heterozygous, %

44 (28)

13 (15.6)

0.08

9 (37.5)

0.19

APOE ε4 homozygous, %

5 (3.1)

11 (13.3)

0.008

3 (12.5)

0.019

MMSE, mean (SD)

28.97 (1.33)

28.05 (2.15)

<0.0001

19.67 (5.28)

<0.0001

CDR SoB, mean (SD)

0.009 (0.51)

1.46 (0.93)

<0.0001

7.18 (2.67)

<0.0001

[18F]Florbetapir SUVR, (SD)

1.2 (0.22)

1.26 (0.29)

0.07

1.47 (0.22)

<0.0001

Braak 1&2 [18F]Flortaucipir SUVR, (SD)

1.14 (0.13)

1.21 (0.2)

<0.0001

1.4 (0.233)

<0.0001

Braak 3&4 [18F] Flortaucipir SUVR, (SD)

1.08 (0.09)

1.15 (0.2)

<0.0001

1.46 (0.43)

<0.0001

Braak 5&6 [18F] Flortaucipir SUVR, (SD)

0.99 (0.09)

1.06 (0.18)

<0.0001

1.25 (0.34)

<0.0001

(C) ADNI lumbar puncture cohort

CN

MCI

P value

AD

P value

No.

104

283

–

100

–

Age, years, mean (SD)

73.66 (6.41)

72.1 (7.31)

0.06

74.21 (8.06)

0.59

Male, no. (%)

54 (51.9)

153 (54.06)

0.14

61 (61)

0.19

Education, years, mean (SD)

16.6 (2.58)

16.15 (2.59)

0.13

15.85 (2.64)

0.04

APOE ε4 heterozygous, %

21 (20.19)

112 (39.58)

0.0001

48 (48)

0.0001

APOE ε4 homozygous, %

6 (5.76)

29 (10.25)

0.0001

18 (18)

0.0001

MMSE, mean (SD)

29.06 (1.34)

27.96 (2.09)

<0.0001

23.18 (5.5)

<0.0001

CDR SoB, mean (SD)

0.05 (0.16)

1.51 (0.9)

<0.0001

4.52 (1.74)

<0.0001

[18F]Florbetapir SUVR, (SD)

1.13 (0.24)

1.22 (0.18)

0.0002

1.36 (0.17)

<0.0001

CSF p-tau pg/mL, (SD)

20.47 (7.88)

26.63 (13.81)

0.002

37.89 (16.79)

<0.0001

CSF p-tau positive, %

30 (29)

146 (52)

<0.0001

82 (82)

<0.0001

  1. CSF p-tau positivity is based on a published cutoff of 23 pg/mL.
  2. P values indicate values assessed with independent samples t tests for each variable except sex and APOE ε4 status, where contingency chi-square tests were performed. P values reported are for comparisons with cognitively normal subjects.
  3. MMSE Mini-Mental State Examination, CDR SoB Clinical Dementia Rating Sum of Boxes; SUVR standardized uptake value ratio, p-tau phosphorylated tau, CN cognitively normal, MCI mild cognitive impairment, AD Alzheimer’s disease.
Back to article page